Equities

Microbot Medical Inc

Microbot Medical Inc

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / --
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Microbot Medical Inc. is a pre-clinical medical device company. The Company is focused on the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms are comprised of ViRob, TipCAT and Liberty, including certain CardioSert assets. Using the ViRob platform, Microbot is developing the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH). Utilizing the Liberty and CardioSert platforms, it is developing disposable robot for various endovascular interventional procedures. ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. TipCAT is a disposable self-propelled locomotive device, designed to advance in tubular anatomies. Liberty is a disposable robotic system, designed to move guidewires and over-the-wire devices, such as microcatheters within the body’s vasculature.

  • Revenue in USD (TTM)0.00
  • Net income in USD-10.01m
  • Incorporated1988
  • Employees12.00
  • Location
    Microbot Medical Inc25 RECREATION PARK DR SUITE 108HINGHAM 02043United StatesUSA
  • Phone+1 (908) 938-5561
  • Fax+1 (302) 655-5049
  • Websitehttp://www.microbotmedical.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.